Modality
Peptide
MOA
SOS1i
Target
TROP-2
Pathway
Neuroinflam
CholangiocarcinomaDravetTTR Amyloidosis
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
~Dec 2021
→ ~Mar 2023
Phase 3
~Jun 2023
→ ~Sep 2024
NDA/BLA
Dec 2024
→ Mar 2028
NDA/BLACurrent
NCT08779347
2,112 pts·TTR Amyloidosis
2024-12→2028-03·Recruiting
2,112 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-232.0y awayPh3 Readout· TTR Amyloidosis
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2028-03-23 · 2.0y away
TTR Amyloidosis
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08779347 | NDA/BLA | TTR Amyloidosis | Recruiting | 2112 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |